Physician

Tarek Chidiac, MD

According to 2025 Medicare claims, Tarek Chidiac, MD (NPI: 1922066778) practices hematology/oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 43219-1530.

Chidiac's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 187 traditional Medicare patients, billed 37,157 HCPCS/CPT codes, and received $947,511 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 813 prescription claims across 165 beneficiaries totaling $4,751,614 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 65 claims. Open Payments data shows 158 records totaling $61,912. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $2,142,648 to $4,751,614. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	276	53,191	$689,288
2016	298	51,253	$622,048
2017	312	56,032	$735,362
2018	346	72,735	$897,186
2019	314	60,175	$1,057,637
2020	241	51,452	$1,173,738
2021	254	61,476	$1,092,931
2022	272	43,314	$822,505
2023	281	41,145	$881,869
2024	187	37,157	$947,511

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	172	1,143	$2,142,648
2016	159	1,039	$2,015,428
2017	161	870	$1,776,879
2018	131	685	$1,138,408
2019	181	981	$1,814,047
2020	156	1,139	$2,189,528
2021	167	1,029	$2,917,448
2022	163	847	$2,813,665
2023	160	771	$3,190,397
2024	165	813	$4,751,614

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	41	$16,797
2016	N/R	N/R	N/R
2017	N/R	50	$12,780
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	46	$4,003
2021	N/R	65	$4,412
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	26	43	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	78	186	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	84	110	$63
36415	Insertion of needle into vein for collection of blood sample	130	336	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	134	363	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	76	2,081	$1,252,249
Brukinsa	Zanubrutinib	41	1,230	$585,784
Doptelet	Avatrombopag Maleate	36	1,121	$496,296
Calquence	Acalabrutinib Maleate	23	690	$351,433
Ibrance	Palbociclib	22	616	$346,020

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	155	$58,912	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$3,000	Alexion Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tarek Chidiac, MD?

Tedicare shows public-source Medicare data for Tarek Chidiac, MD (NPI 1922066778), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tarek Chidiac, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Tarek Chidiac, MD?

Tarek Chidiac, MD is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Tarek Chidiac, MD have Open Payments data?

Tarek Chidiac, MD has 158 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.